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Abstract 
 
Background: Oral anticoagulant therapy is central to the prevention thromboembolic events in 
atrial fibrillation (AF) patients. The SAMe-TT2R2 score is a simple clinical-derived score designed to 
aid decision-making on whether or not a patient is likely to achieve good anticoagulation control 
on Vitamin K Antagonists (VKA, e.g. warfarin). Good anticoagulation control is associated with 
optimal VKA efficacy and safety. 
Methods: The SAMe-TT2R2 score was studied in a large cohort of warfarin-treated non-valvular AF 
patients from the SPORTIF trials, and related to Time in therapeutic range (TTR) as measure of 
anticoagulation control, and thromboembolism-related outcomes. 
Results: Among the 3,665 patients originally assigned to the warfarin arm, a SAMe-TT2R2 score >2 
was found in 19.5%. In these patients, a linear relationship was reported between SAMe-TT2R2 
score and TTR (p<0.001).  SAMe-TT2R2 >2 was inversely associated with a higher proportion with 
TTR >65% (p=0.014) or TTR >70% (p=0.011).  
Patients with SAMe-TT2R2 score >2 had a significantly higher event rate of the composite 
thromboembolism-related outcome, vs SAMe-TT2R2 0-2 (10.2% vs. 7.9%, p=0.045).   
On survival analysis, SAMe-TT2R2 >2 was associated with a higher risk for the composite outcome 
(Log-Rank: 5.471, p=0.019).  On Cox regression, a SAMe-TT2R2 score >2 was independently 
associated with the composite outcome (p=0.020). 
Conclusions: In this large trial cohort of AF patients, the SAMe-TT2R2 score was able to identify 
patients more likely to obtain suboptimal anticoagulation control on VKA, with an increase in 
major thromboembolism-related adverse events consequent upon such poor anticoagulation 
control.    
Key words:  atrial fibrillation, anticoagulation control, warfarin 
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Introduction 
Oral anticoagulation (OAC) is central to the prevention thromboembolic events in patients with 
atrial fibrillation (AF)[1]. Despite the introduction of the non-vitamin K antagonist oral 
anticoagulants (NOACs)[2], many patients worldwide are still treated with the Vitamin K 
antagonists (VKA, e.g. warfarin) for stroke prevention[3,4].  
 
When treating AF patients with VKA, it is important to achieve good anticoagulation control, often 
quantified as the average time in therapeutic range (TTR) between INR 2.0-3.0[5,6].   TTR is closely 
related to efficacy and safety of the VKAs.  Thus, the National Institute for Health and Care 
Excellence (NICE) guidelines recommended a TTR level higher than 65% of the total treatment 
time[7], whereas the European Society of Cardiology advises a TTR higher than 70%[1,8].  Poor 
anticoagulation control while treated with VKA is one consideration, when considering to switch 
from VKA treatment to using a NOAC[9].   
 
When starting a newly diagnosed non-anticoagulated AF patient on a VKA, it would be helpful to 
identify those who are likely to achieve good anticoagulation control if prescribed VKA, whilst 
those less likely to obtain an optimal TTR could be targeted for more regular follow-up and 
monitoring, education or use of a NOAC rather than VKA[9,10].   This would avoid a policy of 
having a ‘trial of warfarin’ for everyone over 6-9 months, during which those with suboptimal TTR 
on VKA would be at risk of thromboembolism and bleeding[11,12]. 
 
Many common clinical factors are associated with the likelihood of achieving a good TTR on a 
VKA[13].  By using these common clinical factors to help guide the decision-making process, a 
simple clinical-based tool was developed, the SAMe-TT2R2 score[13,14]. Patients with SAMe-TT2R2 
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>2 are less likely to achieve an optimal TTR level, i.e. higher than 65%[13].   Since its original 
validation, the SAMe-TT2R2 score has been independently validated in several retrospective and 
prospective cohorts, being able to discriminate those patients likely to do well on VKA treatment, 
in both AF and venous thromboembolism patients[12,15–21].  Importantly, the SAMe-TT2R2 score 
was found to be able to identify those at higher risk of adverse outcomes in various VKA-treated 
‘real world’ observational cohorts[12,16,18].  
 
The aims to this study was first, to evaluate the baseline SAMe-TT2R2 score in a large cohort of 
warfarin-treated non-valvular AF patients from a high-quality, well-conducted multicentre 
international randomized clinical trial (RCT) population. Second, we evaluated the predictive value 
of SAMe-TT2R2 score >2 for TTR, independent from prior VKA therapy use.  Third, we assessed the 
adverse outcomes related to high SAMe-TT2R2 score (and thus, poor TTR), i.e. clinically relevant 
major thromboembolic adverse events, 
 
Methods 
For the present study, we analysed the pooled datasets from the Stroke Prevention using an Oral 
Thrombin Inhibitor in patients with atrial Fibrillation (SPORTIF) III and V studies[22–24]. The 
SPORTIF trials were two multicentre global phase III clinical trials comparing the efficacy and 
safety of the direct thrombin inhibitor, ximelagatran, against warfarin in patients with non-valvular 
AF.  SPORTIF III was an open label trial, while SPORTIF V was a double blind study[22]. In the 
purposes of this study, we only considered the patients assigned to the warfarin arm, as the 
development of ximelagatran has been discontinued and thus, the results less relevant for clinical 
practice. 
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The SAMe-TT2R2 score was calculated (as was previously defined[13]): one point was assigned for 
female sex; age below 60 years; at least two comorbidities in the previous medical history; and 
treatment with VKA-interacting drugs; whilst two points were given for current smoking habit and 
non-Caucasian race.  The study population was divided in two categories:  (i) patients with SAMe-
TT2R2 0-2, who were likely to do well on warfarin; and (ii) patients with SAMe-TT2R2>2, who were 
less likely to achieve good anticoagulation control. 
 
Thromboembolic risk was categorised according to CHA2DS2-VASc scores[25]. “Low risk” patients 
were defined as males with a CHA2DS2-VASc =0 or females with CHA2DS2-VASc =1; “moderate risk” 
was defined as male patients with CHA2DS2-VASc=1; and “high risk” with CHA2DS2-VASc ≥2. 
 
Anticoagulation control, as reflected by the TTR was calculated using the standardized Rosendaal 
interpolation method[5], by assigning an INR value to each day between two successive observed 
INR values, and the percentage of time that the interpolated INR remains between 2 and 3 was 
used to establish TTR value. In order to verify predictive abilities of SAMe-TT2R2 on different TTR 
levels, we established three different cut-off points (TTR > 60%, TTR > 65% and TTR > 70%) as 
sensitivity analyses. 
 
Study Outcomes in Warfarin-Treated Patients 
Major outcomes were defined according to the original trial protocol, and independently 
adjudicated by an events committee blinded to the trial treatment assignment[22].  To evaluate if 
SAMe-TT2R2 could identify patients at higher risk for the major adverse events related to poor TTR, 
a composite outcome of thromboembolism-related complications, that is ‘stroke/systemic 
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embolic event (SEE)/myocardial infarction (MI)/all-cause death’ was considered.  The relation to 
major bleeding, as defined according to trial study protocol were also investigated [22].  
 
Statistical Analysis 
Non-normally distributed variables were expressed as median and interquartile range (IQR) and 
differences tested using the Mann-Whitney U test. Categorical variables, expressed as counts and 
percentages, were analysed by chi-squared test.  A linear regression analysis between SAMe-TT2R2 
and TTR, adjusted for type of AF and previous VKA use, was performed. Moreover, a logistic 
regression analysis, adjusted for type of AF and previous VKA use, was performed to establish the 
predictive ability of SAMe-TT2R2 for TTR cut-offs, based on SAMe-TT2R2 as a continuous variable 
and SAMe-TT2R2 categories (0-2, >2). 
 
A Log-Rank test was performed for SAMe-TT2R2 as a continuous variable and SAMe-TT2R2 
categories, and the differences in survival between subgroups were reported as Kaplan-Meier 
curves. A forward stepwise Cox proportional hazards model, adjusted for type of AF and previous 
VKA use, according both to SAMe-TT2R2 as a continuous variable and SAMe-TT2R2 categories was 
performed. All analyses were performed using SPSS v. 22.0 (IBM, NY, USA). 
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Results 
 
From the original study cohort of 7,329 patients, 3,665 (50.0%) were assigned to the warfarin 
treatment group. Median age was 72 [IQR 66-77] years, and 1,116 (30.5%) were female. From the 
warfarin treated arm, 715 patients (19.5%) were categorized as SAMe-TT2R2 >2, with those with 
SAMe-TT2R2 score= 1 being the most prevalent subgroup [Figure 1]. 
 
Baseline characteristics of patients according to SAMe-TT2R2 categories are reported in Table 1. 
Patients with SAMe-TT2R2 >2 were younger, more commonly female, smokers and diagnosed with 
hypertension and diabetes mellitus (all p<0.001). Moreover, patients with SAMe-TT2R2 >2 had a 
higher prevalence of coronary heart disease (CHD), chronic heart failure (CHF) [both p<0.001] and 
previous stroke or transient ischemic attack (TIA) (p=0.030).  
 
SAMe-TT2R2 and TTR Levels 
TTR was available for 3,624 (98.9%) patients, with median TTR being 68.50% [IQR 55.17-79.32]. 
TTR values progressively decreased with increasing SAMe-TT2R2 score points (p=0.002) [Table 2]. 
Patients with SAMe-TT2R2 >2 had a significantly lower median TTR value compared to patients 
with SAMe-TT2R2 0-2 (p=0.001) [Table 2].  
 
There was a lower proportion of patients with SAMe-TT2R2 >2 with a TTR >65% and TTR >70% 
(p=0.014 and p=0.011, respectively), compared to those with SAMe-TT2R2 0-2 [Figure 2]. A 
numerical difference between patients with SAMe-TT2R2 0-2 and SAMe-TT2R2 >2 was found for 
TTR >60%, of borderline significance (p=0.061).  
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Regression Analyses for SAMe-TT2R2 score and TTR 
Linear regression analysis shows that SAMe-TT2R2 was inversely associated with TTR (standardized 
beta: -0.073, t: -4.470; p<0.001) with an associated linear relationship between SAMe-TT2R2 and 
TTR.  Logistic regression analysis, adjusted for type of AF and previous VKA use, between SAMe-
TT2R2 categories and TTR cut-off points [Table 3] found that SAMe-TT2R2 as a continuous variable 
was inversely associated with all TTR cut-off points (p=0.003, p=0.001 and p=0.001, respectively 
for TTR >60%, TTR >65% and TTR >70%). Using SAMe-TT2R2 categories, a SAMe-TT2R2 score >2 was 
inversely associated with TTR >65% and TTR >70% (p=0.014 and p=0.011, respectively). 
 
Survival Analysis 
After a median follow-up of 563 [IQR 483-651] days, there were a total of 306 (8.3%) events for 
the composite outcome. Patients with SAMe-TT2R2 score >2 had a significantly higher event rate of 
the composite outcome, compared to those with SAMe-TT2R2 score 0-2 (10.2% vs. 7.9%, p=0.045). 
On survival analysis, patients with SAMe-TT2R2 >2 had a significantly higher risk for the occurrence 
of the composite outcome (Log-Rank: 5.471, p=0.019).  
No significant difference was found in event rate for major bleeding was detected for patients 
with SAMe-TT2R2 score 0-2 and those with score >2 (3.5% vs. 3.5%, p=0.970). 
 
On Cox multivariate regression analysis, adjusted for type of AF and previous VKA use, found that 
SAMe-TT2R2 score as a continuous variable was significantly associated with the composite 
outcome (hazard ratio [HR]: 1.14, 95% confidence interval [CI]: 1.04-1.26; p=0.005). Similarly, the 
SAMe-TT2R2 score >2 category was also significantly associated with the composite outcome (HR: 
1.37, 95% CI: 1.05-1.78; p=0.020). 
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Discussion 
In this large trial cohort of non-valvular AF patients, almost 20% of had a SAMe-TT2R2 score >2 at 
baseline and therefore, were predicted to be less likely to achieve good anticoagulation control. 
Indeed, our second principal finding was that a SAMe-TT2R2 >2 was significantly associated with 
poor anticoagulation control, as reflected by a TTR <65% or TTR <70%. Third, a high SAMe-TT2R2 
score, both as a continuous and categorical variable, was significantly associated with adverse 
outcomes related to poor TTR (i.e. clinically relevant major thromboembolic adverse events), but 
not with higher major bleeding rates. 
 
Data on the distribution of the SAMe-TT2R2 score in an AF population has varied in different 
studies[12,15–19].  The proportion of SAMe-TT2R2 >2 ranges from 7% to 45% in prior studies, but 
was 19.5% in the present cohort, perhaps related to the SPORTIF trial protocol which enrolled AF 
patients at moderate-high stroke risk. 
 
The ability of the SAMe-TT2R2 scores in predicting TTR values has been validated in various 
retrospective and prospective cohorts[12,13,15–19]. In the original validation paper, for example, 
the SAMe-TT2R2 score reported good discriminatory ability in identifying patients with the lowest 
TTR percentile[13].  The SAMe-TT2R2 score has also been significantly associated with other 
measures of anticoagulation control, including the proportion of INRs in Range (PINRR) >70%[18] 
and other similar methods (e.g. INR variability, time above range)[19].  Our results underline the 
predictive value of SAMe-TT2R2 in identifying those patients with the lowest TTR values, given the 
clear linear relationship with the continuous SAMe-TT2R2 score point values and progressively 
higher TTR. The predictive value of SAMe-TT2R2 was independent of patients’ prior VKA use. 
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More recently, another large observational study in a primary care setting from Spain found that 
the SAMe-TT2R2 score was able to significantly predict TTR levels although the discriminatory 
ability was modest, and given the retrospective design of the study, this should be interpreted 
cautiously [26].   Moreover, the study cohort was part of a study investigating anticoagulation 
control in non-valvular AF, so patients were well controlled and TTR assessed intensively [26]. 
Another hospital-based registry study in Hong Kong Chinese reported for the very first time that 
SAMe-TT2R2 was effective in identifying Asian AF patients who were less likely to perform well on 
VKAs [27]. I The SAMe-TT2R2 score was also able to predict TTR levels in patients with venous 
thromboembolism who are initiated on VKA therapy [21]. 
 
  As far as we are aware, the predictive ability of SAMe-TT2R2 has only been reported in several 
moderate-sized ‘real world’ cohorts[12,16,18]. In a large observational cohort of non-valvular AF 
patients, a SAMe-TT2R2 >2 was predictive of labile INR, as the associated sequelae such as 
thromboembolism, bleeding and death[12].  Abumuaileq et al. reported that SAMe-TT2R2 was 
associated with the composite outcome of thromboembolic events, all-cause death and major 
bleeding (HR: 1.32, p=0.006) and all-cause death (HR: 1.3). Thromboembolic events alone were 
not significantly increased (HR: 1.01, p=0.90), given the low number of events recorded (1.6% of 
patients)[18]. Similarly, Gallego et al. reported that SAMe-TT2R2 was associated with the 
composite outcome of all adverse cardiovascular events (p<0.001) and all-cause death 
(p=0.001)[16]. In the Asian cohort discussed above, patients with a high SAMe-TT2R2 score (hence, 
more likely to have poor TTR) were at higher risk for incident ischemic stroke [27]. Our data 
reinforce the concept that SAMe-TT2R2 is useful in predicting a clinically relevant composite 
outcome of clinical trial adjudicated major adverse thromboembolism-related outcomes for AF 
patients.  Previously reported data about predictive value of SAMe-TT2R2 for major adverse events 
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have been reported in VKA-naïve cohorts, different from our cohort which included 21.0% who 
had prior VKA use. 
 
Use of the SAMe-TT2R2 score may help decision making when deciding on OAC therapy for stroke 
prevention in AF[10]. Patients with a SAMe-TT2R2 score 0-2 would identify patients likely to 
achieve good anticoagulation control, whilst those with a score >2 would predict those patients 
less likely to achieve good TTR and would help clinicians target these patients for more careful 
follow-up reviews and more intensive education and counselling about VKA therapy, or 
conversely, prescription of a NOAC (rather than impose a ‘trial of warfarin’, which may put the 
patient at risk of thromboembolism due to suboptimal TTR)[6].  Our results also underline how 
calculation of the simple SAMe-TT2R2 score could help clinicians personalize the optimal approach 
to using OAC therapy[9].  This is highly relevant since VKA remains the most widely used OAC 
worldwide, or some healthcare systems still mandate a ‘trial of warfarin’ for 6-9 months before a 
NOAC can be prescribed, usually for cost reasons.  Thus, the SAMe-TT2R2 score may potentially aid 
clinical decision making for stroke prevention in AF, and prospective clinical trials testing such a 
strategy are needed. 
 
Limitations and future directions 
The main limitation is the post-hoc nature of this study, and the study was not specifically 
powered to detect differences according to individual SAMe-TT2R2 points. Since the original trials 
were run between 2000 and 2002, current clinical practice in managing AF patients could have 
changed, with implications for the generalizability of our results.  Further studies are needed to 
investigate if a SAMe-TT2R2 stratified management approach would improve adherence to 
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treatment and prediction of outcomes in an adequately powered long-term follow-up study of 
non-valvular AF patients. 
 
Conclusions 
In this large trial cohort of non-valvular AF patients, the SAMe-TT2R2 score was able to identify 
patients more likely to obtain suboptimal anticoagulation control on VKA with an increase in major 
thromboembolism-related adverse events consequent upon such poor anticoagulation control.   
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Table 1: Baseline Characteristics of Patients According to SAMe-TT2R2 Category 
 SAMe-TT2R2 0-2 
N=2,950 
SAMe-TT2R2 >2 
N=715 
p 
Age, years median [IQR] 73 [67-78] 68 [59-75] <0.001 
Females, n (%) 787 (26.7) 329 (46.0) <0.001 
BMI, median [IQR] 28.1 [25.2-31.6] 27.7 [24.3-32.5] 0.263 
Type of Atrial Fibrillation 3,663 
Paroxysmal, n (%) 
Chronic, n (%) 
 
321 (10.9) 
2,627 (89.1) 
 
73 (10.2) 
642 (89.8) 
0.599 
Hypertension, n (%) 2,214 (75.1) 598 (83.6) <0.001 
Diabetes, n (%) 600 (20.3) 260 (36.4) <0.001 
Smoking Habit, n (%) 52 (1.8) 282 (39.4) <0.001 
Coronary Heart Disease, n (%) 1,241 (42.1) 378 (52.9) <0.001 
Chronic Heart Failure, n (%) 1,017 (34.5) 355 (49.7) <0.001 
Previous Stroke/TIA, n (%) 585 (19.8) 168 (23.5) 0.030 
Previous Bleeding, n (%) 176 (6.0) 32 (4.5) 0.124 
Aspirin Use, n (%) 3,662 565 (19.2) 161 (22.5) 0.042 
Previous VKA Use, n (%) 2,335 (79.2) 561 (78.5) 0.684 
Thromboembolic Risk 
Low Risk, n (%) 
Moderate Risk, n (%) 
High Risk, n (%) 
 
9 (0.3) 
369 (12.5) 
2,572 (87.2) 
 
0 (0.0) 
109 (15.2) 
606 (84.8) 
0.053 
Legend: BMI= body mass index; IQR= Intequartile Range, TIA= Transient Ischemic Attack. 
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Table 2: TTR Values According to SAMe-TT2R2 
 N (%) TTR 
Median [IQR] 
p 
SAMe-TT2R2 
0 
1 
2 
3 
4 
5-7 
 
547 (15.1) 
1,228 (33.9) 
1,139 (31.4) 
463 (12.8) 
80 (5.0) 
67 (1.8) 
 
70.36 [59.39-81.54] 
69.03 [55.07-80.01] 
68.31 [55.00-79.08] 
67.01 [52.50-77.49] 
66.91 [54.04-77.73] 
63.82 [48.56-76.97] 
0.002 
SAMe-TT2R2 Category 
0-2 
>2 
 
2,914 (80.4) 
710 (19.6) 
 
69.05 [55.63-79.89] 
66.55 [52.83-77.46] 
0.001 
Legend: IQR= Interquartile Range; TTR= Time in Therapeutic Range. 
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Table 3: Logistic Regression Analysis* of SAMe-TT2R2 score to TTR Cut-Off Points 
 TTR >60% TTR >65% TTR >70% 
 OR 95% CI p OR 95% CI p OR 95% CI p 
SAMe-TT2R2 (as per point) 0.91 0.86-0.97 0.003 0.91 0.86-0.96 0.001 0.91 0.86-0.96 0.001 
SAMe-TT2R2 >2 0.85 0.71-1.01 0.060 0.81 0.69-0.96 0.014 0.81 0.68-0.95 0.011 
Legend: TTR= Time in Therapeutic Range; *adjusted for type of atrial fibrillation and previous vitamin K antagonist use. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 20 
FIGURE LEGENDS 
 
Figure 1: Distribution of Patients According to SAMe-TT2R2 
Figure 2: TTR Levels According to SAMe-TT2R2 Categories 
Legend: TTR= Time in Therapeutic Range. 
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Fig. 2 
